Astellas reorganizes European business

12 August 2007

Japanese drug major Astellas Pharma says that its board of directors has decided to reorganize the development, sales and marketing and other support functions within the group's European business.

Astellas' European business has many functions including: R&D, production and sales and marketing, which comprises export operations and employs 3,300 people. With sales of 219.6 billion yen ($1.84 billion) for the fiscal year 2006, which ended March 31, 2007, this is the second largest operation within the company. Astellas, in its medium-term plan, has positioned the European business as a stable revenue and profit base and has transferred three of its production plants in Europe to a third party on January 1; the reorganization now decided on does not affect the manufacturing function but aims to further optimize the European business.

The main changes for the group as a result of this reorganization include:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight